Global pharmaceutical supply chains are entering an era of unprecedented trade volatility, shifting tariff structures, regulatory complexity, and geopolitical disruption. While these external pressures are often viewed as compliance challenges, they are increasingly shaping network design, sourcing strategies, speed-to-patient initiatives, and long-term supply chain resilience. Erika Vidal-Faulkenberry will provide a forward-looking perspective on how trade dynamics are transforming end-to-end pharmaceutical supply chains, from early development through commercialization. Drawing on cross-industry experience and global trade leadership, this discussion will explore how organizations can anticipate disruption, challenge legacy operating assumptions, and proactively embed trade considerations into strategic supply chain decision-making.

• Proactively factor tariffs, regulatory shifts, and geopolitical risk into sourcing, manufacturing, and distribution decisions to minimize disruption and protect supply continuity
• Strengthen end-to-end collaboration across development, clinical & commercial supply chains and understand how trade requirements impact each stage of the product lifecycle and how cross-functional alignment can accelerate speed-to-patient while reducing compliance risk
• Gain actionable strategies to increase organizational agility, evaluate alternative network models, and challenge legacy supply chain assumptions in an increasingly complex global trade environment